Abstract
Background: Chemerin is an adipokine that induces insulin resistance by the mechanism of inflammation in adipose tissue but these are still unclear. A high level of chemerin in humans is considered as a marker of inflammation in insulin resistance and obesity as well as in type 2 diabetes mellitus. Despite the role of chemerin in insulin resistance progression, chemerin as one of the novel adipokines is proposed to be involved in high cancer risk and mortality.
Aim: The aim of this paper was to review the role of CMKLR-1 receptor and the potential therapeutic target in the management of chemerin induced type 2 diabetes mellitus and cancer.
Pathophysiology: Increased chemerin secretion activates an inflammatory response. The inflammatory response will increase the oxidative stress in adipose tissue and consequently results in an insulin-resistant state. The occurrence of inflammation, oxidative stress and insulin resistance leads to the progression of cancers.
Conclusion: Chemerin is one of the markers that may involve in development of both cancer and insulin resistance. Chemokine like receptor- 1 (CMKLR-1) receptor that regulates chemerin levels exhibits a potential therapeutic target for insulin resistance, type 2 diabetes and cancer treatment.
Keywords: Chemerin, insulin resistance, type 2 diabetes mellitus, cancer, chemokine-like receptor 1, therapeutic target, obesity, inflammation.
Current Pharmaceutical Design
Title:Chemokine Like Receptor-1 (CMKLR-1) Receptor: A Potential Therapeutic Target in Management of Chemerin Induced Type 2 Diabetes Mellitus and Cancer
Volume: 23 Issue: 25
Author(s): Sangeetha Perumalsamy, Nurul Ain Aqilah Mohd Zin, Riyanto Teguh Widodo, Wan Azman Wan Ahmad , Shireene Ratna D.B. Vethakkan and Hasniza Zaman Huri*
Affiliation:
- Department of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur,Malaysia
Keywords: Chemerin, insulin resistance, type 2 diabetes mellitus, cancer, chemokine-like receptor 1, therapeutic target, obesity, inflammation.
Abstract: Background: Chemerin is an adipokine that induces insulin resistance by the mechanism of inflammation in adipose tissue but these are still unclear. A high level of chemerin in humans is considered as a marker of inflammation in insulin resistance and obesity as well as in type 2 diabetes mellitus. Despite the role of chemerin in insulin resistance progression, chemerin as one of the novel adipokines is proposed to be involved in high cancer risk and mortality.
Aim: The aim of this paper was to review the role of CMKLR-1 receptor and the potential therapeutic target in the management of chemerin induced type 2 diabetes mellitus and cancer.
Pathophysiology: Increased chemerin secretion activates an inflammatory response. The inflammatory response will increase the oxidative stress in adipose tissue and consequently results in an insulin-resistant state. The occurrence of inflammation, oxidative stress and insulin resistance leads to the progression of cancers.
Conclusion: Chemerin is one of the markers that may involve in development of both cancer and insulin resistance. Chemokine like receptor- 1 (CMKLR-1) receptor that regulates chemerin levels exhibits a potential therapeutic target for insulin resistance, type 2 diabetes and cancer treatment.
Export Options
About this article
Cite this article as:
Perumalsamy Sangeetha , Aqilah Mohd Zin Ain Nurul , Widodo Teguh Riyanto , Wan Ahmad Azman Wan , Vethakkan Ratna D.B. Shireene and Huri Zaman Hasniza *, Chemokine Like Receptor-1 (CMKLR-1) Receptor: A Potential Therapeutic Target in Management of Chemerin Induced Type 2 Diabetes Mellitus and Cancer, Current Pharmaceutical Design 2017; 23(25) . https://dx.doi.org/10.2174/1381612823666170616081256
DOI https://dx.doi.org/10.2174/1381612823666170616081256 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Immunotherapy in Liver Diseases: A Balance Between Immunity and Tolerance
Current Drug Metabolism History and Milestones of Mouse Models of Autoimmune Diseases
Current Pharmaceutical Design Drainage of Cerebral Abscesses Prior to Valve Replacement in Stable Patients with Acute Left-Sided Infective Endocarditis
CNS & Neurological Disorders - Drug Targets Editorial [Hot topic:Current Hypertension Reviews, Hot Topics “Obesity, Hypertension, and the Metabolic Syndrome” (Guest Editor: Kazuko Masuo)]
Current Hypertension Reviews Therapeutic Potential of Modulating MicroRNA in Peripheral Artery Disease
Current Vascular Pharmacology Exploring the Potential of NO-Independent Stimulators and Activators of Soluble Guanylate Cyclase for the Medical Treatment of Erectile Dysfunction
Current Pharmaceutical Design Metabolic Control and Diabetic Retinopathy
Current Diabetes Reviews New Aspects of Statin Safety
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Experimental Rodent Models of Vascular Dementia: A Systematic Review
CNS & Neurological Disorders - Drug Targets Tocilizumab: From Rheumatic Diseases to COVID-19
Current Pharmaceutical Design Epigenetic Effects of Environmental Chemicals on Reproductive Biology
Current Drug Targets Folate Nutrigenetics: A Convergence of Dietary Folate Metabolism, Folic Acid Supplementation, and Folate Antagonist Pharmacogenetics
Drug Metabolism Letters Specific Nutritional Needs for Children: Are Children Small Adults?
Current Pediatric Reviews Anti-Diabetic
Current Bioactive Compounds Neuronal and Glial Cell Abnormality as Predictors of Progression of Diabetic Retinopathy
Current Pharmaceutical Design Sympathetic Overactivity in Hypertension and Cardiovascular Disease
Current Vascular Pharmacology Brain Tumor Causes, Symptoms, Diagnosis and Radiotherapy Treatment
Current Medical Imaging Primary Prevention of Cardiovascular Risk in Octogenarians by Risk Factors Control
Current Hypertension Reviews Cellular Mechanisms of Bypass Vein Graft Arterialization and Approaches to Attenuate Graft Remodeling
Vascular Disease Prevention (Discontinued) Adipose Tissue Oxygenation in Obesity: A Matter of Cardiovascular Risk?
Current Pharmaceutical Design